Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents

View ORCID ProfileSarah E. Messiah, Frances Brito, Harold W. Kohl III, Stacia DeSantis, Melissa Valerio-Shewmaker, Jessica Ross, Michael D. Swartz, Ashraf Yaseen, Steven H. Kelder, Shiming Zhang, Onyinye S Omega-Njemnobi, Michael O. Gonzalez, Leqing Wu, Eric Boerwinkle, David Lakey, Jennifer A. Shuford, Stephen J. Pont
doi: https://doi.org/10.1101/2021.11.21.21266484
Sarah E. Messiah
aThe University of Texas Health Science Center at Houston, School of Public Health in Dallas, Dallas, TX, USA
bCenter for Pediatric Population Health, The University of Texas Health Science Center at Houston, School of Public Health and Children’s Health System of Texas, Dallas, TX, USA
PhD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarah E. Messiah
  • For correspondence: Sarah.E.Messiah@uth.tmc.edu
Frances Brito
cThe University of Texas Health Science Center at Houston, School of Public Health in Houston, Houston, TX, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harold W. Kohl III
dThe University of Texas Health Science Center at Houston, School of Public Health in Austin, Austin, TX, USA
eUniversity of Texas at Austin, Austin, TX, USA
PhD, MSPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stacia DeSantis
cThe University of Texas Health Science Center at Houston, School of Public Health in Houston, Houston, TX, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa Valerio-Shewmaker
fThe University of Texas Health Science Center at Houston, School of Public Health in Brownsville, Brownsville, TX, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Ross
BSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Swartz
cThe University of Texas Health Science Center at Houston, School of Public Health in Houston, Houston, TX, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashraf Yaseen
cThe University of Texas Health Science Center at Houston, School of Public Health in Houston, Houston, TX, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven H. Kelder
dThe University of Texas Health Science Center at Houston, School of Public Health in Austin, Austin, TX, USA
PhD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shiming Zhang
cThe University of Texas Health Science Center at Houston, School of Public Health in Houston, Houston, TX, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Onyinye S Omega-Njemnobi
dThe University of Texas Health Science Center at Houston, School of Public Health in Austin, Austin, TX, USA
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael O. Gonzalez
cThe University of Texas Health Science Center at Houston, School of Public Health in Houston, Houston, TX, USA
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leqing Wu
cThe University of Texas Health Science Center at Houston, School of Public Health in Houston, Houston, TX, USA
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Boerwinkle
cThe University of Texas Health Science Center at Houston, School of Public Health in Houston, Houston, TX, USA
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Lakey
gThe University of Texas System, Austin, TX, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer A. Shuford
hTexas Department of State Health Services, Austin, TX, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen J. Pont
hTexas Department of State Health Services, Austin, TX, USA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Recent data suggest the SARS-CoV-2 Delta (B.1.617.2) variant is more transmissible among children compared to the Alpha (B.1.1.7) variant. The true incidence and longitudinal presence of antibody response to SARS-CoV-2 infection is not known, however. We provided estimates of antibody response using Texas Coronavirus Antibody REsponse Survey (Texas CARES) data, a prospective population-based seroprevalence project designed to assess antibody status over time among the general population throughout the state.

Methods In October 2020 Texas CARES began enrolling adults (aged 20-80 years) and children (aged 5-19 years). Participants were offered a series of three SARS-CoV-2 antibody tests over 6-8 months, or every 2-3 months that includes the immunoassay for detection of antibodies to the SARS-CoV-2 nucleocapsid protein (Roche N-test). Descriptive characteristics and COVID-19 infection-related symptom status was determined by questionnaire at the time of enrollment and prior to each successive blood draw. This analysis included participants ages 5-to-19 years old who have completed all three antibody assessments.

Results From our sample (n=159; mean age 12.5 years, SD 3.6), 96% of those with evidence of nucleocapsid antibodies at baseline assessment continued to have antibodies > six months later (mean 7.0 months, SD 0.97). There was no difference in the presence of antibodies by symptom status (asymptotic versus symptomatic) or severity (mild-moderate versus severe), sex, age group, or body mass index group (underweight, healthy weight, overweight, obesity) over the three antibody measurement timepoints.

Conclusions These results suggest that infection-induced antibodies persist and thus may provide some protection against future infection for at least half a year. 57.9% of the sample were negative for infection-induced antibodies at their third measurement point, suggesting a significant proportion of children have still not acquired natural infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by Texas Department of State Health Services (Contract #HHS000866600001).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All protocols were reviewed and approved by the University of Texas Health Science Center, Committee for the Protection of Human Subjects, but also deemed public health practice by the Texas Department of State Health Services IRB.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of Interest Disclosures (includes financial disclosures): We have no disclosures to report, financial or otherwise

  • Funding Support: Texas Department of State Health Services (Contract #HHS000866600001).

  • Role of Funder: The Texas Department of State Health Services (DSHS) had no role in the study design, data collection and analysis. Drs. Pont and Shuford are DSHS collaborators on this project. They assisted in the interpretation of data, in the writing of this report, and in the decision to submit this paper for publication.

  • Clinical Trials Registration: N/A

Data Availability

Texas CARES investigators are committed to data sharing. Granular results and user-specified data summaries are currently publicly available on the Texas CARES portal (https://sph.uth.edu/projects/texascares/dashboard). When baseline recruitment is complete, a deidentified individual level dataset will be available for download from the same portal.

https://sph.uth.edu/projects/texascares/dashboard

  • Abbreviations

    COVID-19
    coronavirus disease 2019
    DSHS
    Department of State Health Services
    SARS-CoV-2
    severe acute respiratory syndrome coronavirus 2
    Texas CARES
    Texas COVID-19 Antibody Response Survey
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
    Back to top
    PreviousNext
    Posted November 24, 2021.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents
    Sarah E. Messiah, Frances Brito, Harold W. Kohl III, Stacia DeSantis, Melissa Valerio-Shewmaker, Jessica Ross, Michael D. Swartz, Ashraf Yaseen, Steven H. Kelder, Shiming Zhang, Onyinye S Omega-Njemnobi, Michael O. Gonzalez, Leqing Wu, Eric Boerwinkle, David Lakey, Jennifer A. Shuford, Stephen J. Pont
    medRxiv 2021.11.21.21266484; doi: https://doi.org/10.1101/2021.11.21.21266484
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Durability of SARS-CoV-2 Antibodies from Natural Infection in Children and Adolescents
    Sarah E. Messiah, Frances Brito, Harold W. Kohl III, Stacia DeSantis, Melissa Valerio-Shewmaker, Jessica Ross, Michael D. Swartz, Ashraf Yaseen, Steven H. Kelder, Shiming Zhang, Onyinye S Omega-Njemnobi, Michael O. Gonzalez, Leqing Wu, Eric Boerwinkle, David Lakey, Jennifer A. Shuford, Stephen J. Pont
    medRxiv 2021.11.21.21266484; doi: https://doi.org/10.1101/2021.11.21.21266484

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Pediatrics
    Subject Areas
    All Articles
    • Addiction Medicine (280)
    • Allergy and Immunology (579)
    • Anesthesia (140)
    • Cardiovascular Medicine (1947)
    • Dentistry and Oral Medicine (252)
    • Dermatology (185)
    • Emergency Medicine (333)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (700)
    • Epidemiology (11108)
    • Forensic Medicine (8)
    • Gastroenterology (626)
    • Genetic and Genomic Medicine (3182)
    • Geriatric Medicine (309)
    • Health Economics (563)
    • Health Informatics (2043)
    • Health Policy (863)
    • Health Systems and Quality Improvement (782)
    • Hematology (310)
    • HIV/AIDS (682)
    • Infectious Diseases (except HIV/AIDS) (12729)
    • Intensive Care and Critical Care Medicine (707)
    • Medical Education (317)
    • Medical Ethics (92)
    • Nephrology (336)
    • Neurology (2993)
    • Nursing (164)
    • Nutrition (465)
    • Obstetrics and Gynecology (589)
    • Occupational and Environmental Health (614)
    • Oncology (1556)
    • Ophthalmology (478)
    • Orthopedics (185)
    • Otolaryngology (266)
    • Pain Medicine (202)
    • Palliative Medicine (57)
    • Pathology (403)
    • Pediatrics (914)
    • Pharmacology and Therapeutics (382)
    • Primary Care Research (355)
    • Psychiatry and Clinical Psychology (2789)
    • Public and Global Health (5597)
    • Radiology and Imaging (1095)
    • Rehabilitation Medicine and Physical Therapy (635)
    • Respiratory Medicine (761)
    • Rheumatology (339)
    • Sexual and Reproductive Health (311)
    • Sports Medicine (289)
    • Surgery (343)
    • Toxicology (48)
    • Transplantation (159)
    • Urology (133)